论文部分内容阅读
目的研究miR-34c对喉癌细胞株人喉癌表皮细胞(Hep-2)的细胞周期及细胞增殖的影响。方法将Hep-2分为转染miR-34c寡聚核苷酸组(A组)、转染无义序列组(B组)和空白对照组(C组)。采用RT-PCR、MTT法、流式细胞术及Western blot技术评价各组细胞增殖和细胞周期的生物学变化。结果转染miR-34c寡聚核苷酸后,Hep-2中miR-34c的表达上调;与C组相比,A组细胞增殖水平明显抑制。miR-34c寡聚核苷酸能够有效诱导Hep-2细胞周期阻滞在G1/G0期;A组细胞分裂周期蛋白42(CDC42)表达水平下调,cyclin依赖型激酶(CDK4)表达水平降低。结论 miR-34c寡聚核苷酸能够抑制喉癌细胞Hep-2的增殖;miR-34c是潜在的人喉癌细胞基因治疗的候选靶点。
Objective To study the effect of miR-34c on the cell cycle and cell proliferation of human laryngeal carcinoma cell line Hep-2. Methods Hep-2 cells were divided into group A (transfected with miR-34c), transfected with nonsense sequence (group B) and blank control group (group C). The biological changes of cell proliferation and cell cycle in each group were evaluated by RT-PCR, MTT, flow cytometry and Western blot. Results The miR-34c expression was up-regulated in Hep-2 cells transfected with miR-34c oligonucleotides. Compared with group C, the proliferation of group A was significantly inhibited. miR-34c oligodeoxynucleotides can effectively induce the arrest of Hep-2 cell cycle in G1 / G0 phase; while the expression of CDC42 in group A is down-regulated and the expression of cyclin-dependent kinase (CDK4) is decreased. Conclusion miR-34c oligodeoxynucleotides can inhibit the proliferation of laryngeal carcinoma Hep-2 cells. MiR-34c is a potential target for gene therapy of human laryngeal carcinoma cells.